Autopsy report · NCT00042315
A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Phase III Study of Tariquidar + Vinorelbine as First-Line Therapy in Non-Small Cell Lung Cancer (NSCLC)
Cause of deathNo reason given
Life of this trial
- Registered 1 month after it had already started.
- Ran for about 1 year before it stopped.
- 490 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 3
- Sponsor
- QLT Inc.
- Sponsor type
- Industry
- Conditions
- Stage IIIb Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer
- Interventions
- Chemotherapy; tariquidar + vinorelbine; placebo + vinorelbine
- Participants
- 490
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.